With Successful Prosecution of CEO, DOJ Raises the Stakes for Corporate Executives

Feb 11, 2022

Posted by Sidley Austin

EdiGene Announces Publication by Company Scientific Founder in Nature Biotechnology of LEAPER™ 2.0, an Updated Version of the RNA Base Editing Technology using Engineered Circular ADAR-recruiting RNA

Feb 11, 2022

Posted by EdiGene

EdiGene and Neukio Enter Collaboration to Develop Next-Generation Immune Cell Therapies

Feb 11, 2022

Posted by EdiGene

EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

Feb 11, 2022

Posted by EdiGene

EdiGene Enters Research Collaboration to Develop Gene-editing Therapies for Inherited Retinal Degeneration with Peking Union Medical College Hospital

Feb 11, 2022

Posted by EdiGene

EdiGene Enters Strategic R&D Collaboration with Haihe Laboratory of Cell Ecosystem to Develop Hematopoietic Stem Cell Regenerative Therapies and Platform Technologies

Feb 11, 2022

Posted by EdiGene

Global Drug Pricing and Market Access: What to Expect in 2022

Feb 09, 2022

Posted by Sidley Austin

InSphero Further Strengthens Scientific Advisory Board for Liver Diseases by Appointing Professor Nikolai Naoumov

Feb 09, 2022

Posted by InSphero

test

Feb 08, 2022

Posted by PharmaLex US Corporation